Samira Majjaj
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021
28.07.2021Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
28.07.2021Clin Cancer Res 2021
Venet David, Gomez Henry, Semiglazov Vladimir, de Azambuja Evandro, Huober Jens, Nuciforo Paolo, Di Cosimo Serena, Piccart-Gebhart Martine, Loi Sherene, Rothé Françoise, Saura Cristina, Wang Yingbo, Rediti Mattia, Maetens Marion, Fumagalli Debora, Brown David N, Majjaj Samira, Salgado Roberto, Pusztai Lajos, Harbeck Nadia, El-Abed Sarra, Sotiriou Christos
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2019; 25:1434.
15.02.2019Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
15.02.2019Clin Cancer Res 2019; 25:1434
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2017; 23:4323-4334.
05.04.2017HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
05.04.2017Clin Cancer Res 2017; 23:4323-4334
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L